163 related articles for article (PubMed ID: 35534911)
21. A case of resistant hypercalcemia of malignancy with a proposed treatment algorithm.
McMahan J; Linneman T
Ann Pharmacother; 2009 Sep; 43(9):1532-8. PubMed ID: 19622757
[TBL] [Abstract][Full Text] [Related]
22. The effects of combined human parathyroid hormone (1-34) and zoledronic acid treatment on fracture healing in osteoporotic rats.
Li YF; Zhou CC; Li JH; Luo E; Zhu SS; Feng G; Hu J
Osteoporos Int; 2012 Apr; 23(4):1463-74. PubMed ID: 21892678
[TBL] [Abstract][Full Text] [Related]
23. Denosumab treatment for refractory hypercalcemia in a hemodialysis patient with tertiary hyperparathyroidism.
Zhang P; Yu Y; Gao Y; Yuan G; Zhang J; Wang W
Hemodial Int; 2023 Apr; 27(2):E23-E28. PubMed ID: 36719850
[TBL] [Abstract][Full Text] [Related]
24. Meta-analysis of clinical trials to assess denosumab over zoledronic acid in bone metastasis.
Chen J; Zhou L; Liu X; Wen X; Li H; Li W
Int J Clin Pharm; 2021 Feb; 43(1):2-10. PubMed ID: 32964403
[TBL] [Abstract][Full Text] [Related]
25. Treatment of hypercalcaemia of malignancy in adults.
Mc Donald D; Drake MT; Crowley RK
Clin Med (Lond); 2023 Sep; 23(5):503-507. PubMed ID: 37775175
[TBL] [Abstract][Full Text] [Related]
26. PTH(1-34) and zoledronic acid have differing longitudinal effects on juvenile mouse femur strength and morphology.
Bartlow CM; Oest ME; Mann KA; Zimmerman ND; Butt BB; Damron TA
J Orthop Res; 2017 Aug; 35(8):1707-1715. PubMed ID: 27653318
[TBL] [Abstract][Full Text] [Related]
27. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors.
Henry D; Vadhan-Raj S; Hirsh V; von Moos R; Hungria V; Costa L; Woll PJ; Scagliotti G; Smith G; Feng A; Jun S; Dansey R; Yeh H
Support Care Cancer; 2014 Mar; 22(3):679-87. PubMed ID: 24162260
[TBL] [Abstract][Full Text] [Related]
28. Cinacalcet increases renal calcium excretion in PTHrP-mediated hypercalcemia: a case report.
Faiq S; Lavelle K; Hu T; Shoback D; Ku G
BMC Endocr Disord; 2023 Jun; 23(1):133. PubMed ID: 37328745
[TBL] [Abstract][Full Text] [Related]
29. Use of denosumab to treat refractory hypercalcemia in a peritoneal dialysis patient with immobilization and tertiary hyperparathyroidism.
Pratt RM; West ML; Tennankore KK
Perit Dial Int; 2020 Jan; 40(1):103-106. PubMed ID: 32063140
[TBL] [Abstract][Full Text] [Related]
30. Parathyroid hormone expression in a patient with metastatic nasopharyngeal rhabdomyosarcoma and hypercalcemia.
Wong K; Tsuda S; Mukai R; Sumida K; Arakaki R
Endocrine; 2005 Jun; 27(1):83-6. PubMed ID: 16077176
[TBL] [Abstract][Full Text] [Related]
31. Denosumab Versus Zoledronic Acid in the Prevention of Skeletal-related Events in Vulnerable Cancer Patients: A Meta-analysis of Randomized, Controlled Trials.
Chen C; Li R; Yang T; Ma L; Zhou S; Li M; Zhou Y; Cui Y
Clin Ther; 2020 Aug; 42(8):1494-1507.e1. PubMed ID: 32718784
[TBL] [Abstract][Full Text] [Related]
32. A Case of Severe, Prolonged, Refractory Hypophosphatemia After Zoledronic Acid Administration.
Clark SL; Nystrom EM
J Pharm Pract; 2016 Apr; 29(2):172-6. PubMed ID: 26739479
[TBL] [Abstract][Full Text] [Related]
33. Drugs Used in Paediatric Bone and Calcium Disorders.
Cheung MS
Endocr Dev; 2015; 28():277-290. PubMed ID: 26138848
[TBL] [Abstract][Full Text] [Related]
34. Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases.
Ikesue H; Mouri M; Tomita H; Hirabatake M; Ikemura M; Muroi N; Yamamoto S; Takenobu T; Tomii K; Kawakita M; Katoh H; Ishikawa T; Yasui H; Hashida T
Support Care Cancer; 2021 Aug; 29(8):4763-4772. PubMed ID: 33527228
[TBL] [Abstract][Full Text] [Related]
35. Denosumab: a new agent in the management of hypercalcemia of malignancy.
Thosani S; Hu MI
Future Oncol; 2015; 11(21):2865-71. PubMed ID: 26403973
[TBL] [Abstract][Full Text] [Related]
36. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
Henry DH; Costa L; Goldwasser F; Hirsh V; Hungria V; Prausova J; Scagliotti GV; Sleeboom H; Spencer A; Vadhan-Raj S; von Moos R; Willenbacher W; Woll PJ; Wang J; Jiang Q; Jun S; Dansey R; Yeh H
J Clin Oncol; 2011 Mar; 29(9):1125-32. PubMed ID: 21343556
[TBL] [Abstract][Full Text] [Related]
37. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
Fizazi K; Carducci M; Smith M; Damião R; Brown J; Karsh L; Milecki P; Shore N; Rader M; Wang H; Jiang Q; Tadros S; Dansey R; Goessl C
Lancet; 2011 Mar; 377(9768):813-22. PubMed ID: 21353695
[TBL] [Abstract][Full Text] [Related]
38. A Systematic Review Supporting the Endocrine Society Clinical Practice Guideline on the Treatment of Hypercalcemia of Malignancy in Adults.
Seisa MO; Nayfeh T; Hasan B; Firwana M; Saadi S; Mushannen A; Shah SH; Rajjoub NS; Farah MH; Prokop LJ; Wang Z; Fuleihan GE; Drake MT; Murad MH
J Clin Endocrinol Metab; 2023 Feb; 108(3):585-591. PubMed ID: 36545700
[TBL] [Abstract][Full Text] [Related]
39. Hypercalcemia and local production of parathyroid hormone-related protein by a perisellar rhabdomyosarcoma after remote pituitary irradiation.
Florez JC; Burton DW; Arnell PM; Deftos LJ; Klibanski A
Endocr Pract; 2005; 11(3):184-9. PubMed ID: 16239205
[TBL] [Abstract][Full Text] [Related]
40. Denosumab Therapy for Refractory Hypercalcemia Secondary to Squamous Cell Carcinoma of Skin in Epidermolysis Bullosa.
Giri D; Ramakrishnan R; Hayden J; Brook L; Das U; Mughal MZ; Selby P; Dharmaraj P; Senniappan S
World J Oncol; 2015 Apr; 6(2):345-348. PubMed ID: 29147430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
